| Basics |
Exelixis, Inc. Common Stock
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
|
| IPO Date: |
May 1, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$10.08B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.25 | 2.21%
|
| Avg Daily Range (30 D): |
$0.77 | 2.04%
|
| Avg Daily Range (90 D): |
$0.64 | 1.74%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.05M |
| Avg Daily Volume (30 D): |
2.74M |
| Avg Daily Volume (90 D): |
2.37M |
| Trade Size |
| Avg Trade Size (Sh.): |
164 |
| Avg Trade Size (Sh.) (30 D): |
69 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Inst.Trades: |
11,447 |
| Avg Inst. Trade: |
$2.76M |
| Avg Inst. Trade (30 D): |
$3.62M |
| Avg Inst. Trade (90 D): |
$4.58M |
| Avg Inst. Trade Volume: |
.16M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.26M |
| Avg Closing Trade (30 D): |
$13.99M |
| Avg Closing Trade (90 D): |
$15.48M |
| Avg Closing Volume: |
320.84K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2026 |
FY 2024 |
|
Basic EPS
|
|
$.57
|
$1.8
|
|
Diluted EPS
|
|
$.55
|
$1.76
|
|
Revenue
|
$
|
$ 555.45M
|
$ 2.17B
|
|
Gross Profit
|
$
|
$ 536.28M
|
$ 2.09B
|
|
Net Income / Loss
|
$
|
$ 159.62M
|
$ 521.27M
|
|
Operating Income / Loss
|
$
|
$ 186.86M
|
$ 604.62M
|
|
Cost of Revenue
|
$
|
$ 19.17M
|
$ 76.22M
|
|
Net Cash Flow
|
$
|
$ -33.62M
|
$ -45.62M
|
|
PE Ratio
|
|
|
|
|
